|
|
|
|
|
|
|
|
|
|
|
|
BHV-I (IBR)
Control Tools
Diagnostics availability
Commercial diagnostic kits available worldwide
Comments NA
Commercial diagnostic kits available in Europe
Comments NA
Diagnostic kits validated by International, European or National Standards
Comments NA
Diagnostic method(s) described by International, European or National standards
Comments NA
Commercial potential for diagnostic kits in Europe
Comments NA
DIVA tests required and/or available
Comments NA
Opportunities for new developments
Comments NA
Vaccines availability
Commercial vaccines availability (globally)
Comments NA
Commercial vaccines authorised in Europe
Comments NA
Marker vaccines available worldwide
Comments NA
Marker vaccines authorised in Europe
Comments NA
Effectiveness of vaccines / Main shortcomings of current vaccines
Comments NA
Commercial potential for vaccines in Europe
Comments NA
Regulatory and/or policy challenges to approval
Comments NA
Commercial feasibility (e.g manufacturing)
Comments NA
Opportunity for barrier protection
Comments NA
Opportunity for new developments
Comments NA
Pharmaceutical availability
Current therapy (curative and preventive)
Comments NA
Future therapy
Comments NA
Commercial potential for pharmaceuticals in Europe
Comments NA
Regulatory and/or policy challenges to approval
Comments NA
Commercial feasibility (e.g manufacturing)
Comments NA
Opportunities for new developments
Comments NA
New developments for diagnostic tests
Requirements for diagnostics development
Comments NA
Time to develop new or improved diagnostics
Comments NA
Cost of developing new or improved diagnostics and their validation
Comments NA
Research requirements for new or improved diagnostics
Comments NA
Technology to determine virus freedom in animals
Comments NA
New developments for vaccines
Requirements for vaccines development / main characteristics for improved vaccines
Comments NA
Time to develop new or improved vaccines
Comments NA
Cost of developing new or improved vaccines and their validation
Comments NA
Research requirements for new or improved vaccines
Comments NA
New developments for pharmaceuticals
Requirements for pharmaceuticals development
Comments NA
Time to develop new or improved pharmaceuticals
Comments NA
Cost of developing new or improved pharmaceuticals and their validation
Comments NA
Research requirements for new or improved pharmaceuticals
Comments NA
Disease details
Description and characteristics.
Pathogen
Comments NA
Variability of the disease
Comments NA
Stability of the agent/pathogen in the environment
Comments NA
Species involved
Animal infected/carrier/disease
Comments NA
Human infected/disease
Comments NA
Vector cyclical/non-cyclical
Comments NA
Reservoir (animal, environmental)
Comments NA
Description of infection & disease in natural hosts
Transmissibility
Comments NA
Pathogenic life cycle stages
Comments NA
Signs/Morbidity
Comments NA
Incubation period
Comments NA
Mortality
Comments NA
Shedding kinetic patterns
Comments NA
Mechanism of pathogenicity
Comments NA
Zoonotic potential
Reported incidence in humans
Comments NA
Estimated level of under-reporting in humans
Comments NA
Risk of occurence in humans, populations at risk, specific risk factors
Comments NA
Symptoms described in humans
Comments NA
Likelihood of spread in humans
Comments NA
Impact on animal welfare and biodiversity
Both disease and prevention/control measures related
Comments NA
Endangered wild species affected or not (estimation for Europe / worldwide)
Comments NA
Slaughter necessity according to EU rules or other regions
Comments NA
Geographical distribution and spread
Current occurence/distribution
Comments NA
Epizootic/endemic- if epidemic frequency of outbreaks
Comments NA
Seasonal cycle (seasonality)
Comments NA
Speed of spatial spread during an outbreak
Comments NA
Transboundary potential of the disease
Comments NA
Seasonal cycle linked to climate
Comments NA
Distribution of disease or vector linked to climate
Comments NA
Outbreaks linked to extreme weather
Comments NA
Sensitivity of disease or vectors to the effects of climate change (environmental changes/land use)
Comments NA
Route of Transmission
Usual mode of transmission (introduction, means of spread)
Comments NA
Occasional mode of transmission
Comments NA
Conditions that favour spread
Comments NA
Detection and Immune response to infection
Mechanism of host response
Comments NA
Immunological basis of diagnosis
Comments NA
Main means of prevention, detection and control
Sanitary measures
Comments NA
Mechanical and biological control
Comments NA
Diagnostic tools
Comments NA
Vaccines
Comments NA
Therapeutics
Comments NA
Biosecurity measures effective as a preventive measure
Comments NA
Border/trade/movement control sufficient for control
Comments NA
Prevention tools
Comments NA
Surveillance
Comments NA
Past experiences on success (and failures) of prevention, control, eradication in regions outside Europe
Comments NA
Costs of above measures
Comments NA
Disease information from the OIE
Disease notifiable to the OIE
Comments NA
OIE disease card available
Comments NA
OIE Terrestrial Animal Health Code (reference)
Comments NA
OIE Terrestrial Manual (reference)
Comments NA
Socio-economic impact
Zoonosis: Impact on affected individuals and/or aggregated DALY figures
Comments NA
Zoonosis: cost of treatment and control of the disease in humans
Comments NA
Direct impact (a) on production
Comments NA
Direct impact (b) cost of private and public control measures
Comments NA
Indirect impact
Comments NA
Trade implications
Impact on international trade/exports from the EU due to existing regulations
Comments NA
Impact on EU intra-community trade due to existing EU regulations
Comments NA
Impact on national trade due to existing regulations
Comments NA
Main perceived obstacles for effective prevention and control
Comments NA
Main perceived facilitators for effective prevention and control
Comments NA
Sources of information
Name of expert group leader
Comments NA
Name of reviewers
Comments NA
Date of preliminary approval
Comments NA
Date of final approval
Comments NA
|
|
